Interim analysis of the randomized PATSGO trial evaluating the prolongation of adjuvant temozolomide in newly diagnosed glioblastoma patients.

Jean‐François Baurain(Cliniques Universitaires Saint-Luc), Laurette Renard, G Cosnard, C. Mitine, F. Hammouch, Tom Boterberg(Ghent University Hospital), Paul M. Clément(Universitair Ziekenhuis Leuven), Daniel Devriendt, Nicolas Whenham(Cliniques Universitaires Saint-Luc)
Journal of Clinical Oncology
May 20, 2010
10.1200/jco.2010.28.15_suppl.2044
Cited by 2

Related Papers

Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
|New England Journal of Medicine|2021|869
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
|Journal of Clinical Oncology|2009|573
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
|The Lancet Oncology|2016|504
Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
|Journal of Clinical Oncology|2010|445